JP2022500081A - 抗ｔｒｅｍ−２アゴニスト抗体 - Google Patents

抗ｔｒｅｍ−２アゴニスト抗体 Download PDF

Info

Publication number
JP2022500081A
JP2022500081A JP2021538178A JP2021538178A JP2022500081A JP 2022500081 A JP2022500081 A JP 2022500081A JP 2021538178 A JP2021538178 A JP 2021538178A JP 2021538178 A JP2021538178 A JP 2021538178A JP 2022500081 A JP2022500081 A JP 2022500081A
Authority
JP
Japan
Prior art keywords
seq
variable region
chain variable
antibody
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021538178A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022500081A5 (https=
Inventor
デイビッド・ホルツマン
ジェイソン・ウルリック
ホン・ジャン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Washington University in St Louis WUSTL
Original Assignee
Washington University in St Louis WUSTL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Washington University in St Louis WUSTL filed Critical Washington University in St Louis WUSTL
Publication of JP2022500081A publication Critical patent/JP2022500081A/ja
Publication of JP2022500081A5 publication Critical patent/JP2022500081A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2021538178A 2018-09-11 2019-09-11 抗ｔｒｅｍ−２アゴニスト抗体 Pending JP2022500081A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862729458P 2018-09-11 2018-09-11
US62/729,458 2018-09-11
PCT/US2019/050575 WO2020055975A1 (en) 2018-09-11 2019-09-11 Anti-trem-2 agonist antibodies

Publications (2)

Publication Number Publication Date
JP2022500081A true JP2022500081A (ja) 2022-01-04
JP2022500081A5 JP2022500081A5 (https=) 2022-09-20

Family

ID=69777153

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021538178A Pending JP2022500081A (ja) 2018-09-11 2019-09-11 抗ｔｒｅｍ−２アゴニスト抗体

Country Status (13)

Country Link
US (1) US12145988B2 (https=)
EP (1) EP3849598A4 (https=)
JP (1) JP2022500081A (https=)
KR (1) KR20210057113A (https=)
CN (1) CN113164572A (https=)
AU (1) AU2019339452A1 (https=)
BR (1) BR112021004316A2 (https=)
CA (1) CA3111569A1 (https=)
IL (1) IL281201A (https=)
MX (1) MX2021002616A (https=)
SG (1) SG11202102162RA (https=)
WO (1) WO2020055975A1 (https=)
ZA (1) ZA202101537B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
CA3111569A1 (en) 2018-09-11 2020-03-19 Washington University Anti-trem-2 agonist antibodies
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
BR112021015656A2 (pt) 2019-02-20 2021-10-05 Denali Therapeutics Inc. Anticorpos anti-trem2 e métodos de uso dos mesmos
JP2023512450A (ja) 2020-01-13 2023-03-27 デナリ セラピューティクス インコーポレイテッド 抗ｔｒｅｍ２抗体及びその使用方法
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
WO2023192282A1 (en) * 2022-03-28 2023-10-05 Denali Therapeutics Inc. Methods for treating brain glucose hypometabolism
CA3254085A1 (en) * 2022-05-18 2023-11-23 The Brigham And Women's Hospital, Inc. KLRB1 LIAISON AGENTS AND THEIR METHODS OF USE
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
JP2025529287A (ja) 2022-09-06 2025-09-04 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル マルファン症候群の処置のためのｔｒｅｍ－２アゴニスト
WO2024160736A1 (en) * 2023-01-30 2024-08-08 Isar Bioscience Gmbh Human anti-trem2 antibody for treating neurodegenerative disorders
AU2024279278A1 (en) 2023-05-31 2025-12-18 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017062672A2 (en) * 2015-10-06 2017-04-13 Alector Llc Anti-trem2 antibodies and methods of use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US20150140672A1 (en) 2011-12-19 2015-05-21 Washington University Methods for detecting amyloid beta amyloidosis
AU2012359020B2 (en) 2011-12-19 2017-04-13 The Washington University Methods for diagnosing Alzheimer's disease
EP2923209A4 (en) 2012-11-20 2016-04-27 Univ Washington METHOD FOR THE DIAGNOSIS OF DISEASES BY ANALYSIS OF AMYLOID BETA ENRICHMENT KINETICS
WO2015116753A1 (en) * 2014-01-29 2015-08-06 Dana-Farber Cancer Institute, Inc. Antibodies against the muc1-c/extracellular domain (muc1-c/ecd)
CA2955086A1 (en) 2014-08-08 2016-02-11 Alector Llc Anti-trem2 antibodies and methods of use thereof
WO2016064895A1 (en) * 2014-10-20 2016-04-28 The Brigham And Women's Hospital, Inc. Targeting apolipoprotein e (apoe) in neurologic disease
WO2017058866A1 (en) * 2015-09-28 2017-04-06 Precision Immune, Inc. Anti-trem2 antibodies and uses thereof
CN109641961A (zh) * 2016-07-22 2019-04-16 德国神经退行性疾病研究中心 Trem2切割调节剂及其用途
CA3111569A1 (en) 2018-09-11 2020-03-19 Washington University Anti-trem-2 agonist antibodies

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017062672A2 (en) * 2015-10-06 2017-04-13 Alector Llc Anti-trem2 antibodies and methods of use thereof

Also Published As

Publication number Publication date
BR112021004316A2 (pt) 2021-11-03
CA3111569A1 (en) 2020-03-19
MX2021002616A (es) 2021-05-12
ZA202101537B (en) 2022-07-27
US12145988B2 (en) 2024-11-19
EP3849598A4 (en) 2022-07-06
CN113164572A (zh) 2021-07-23
IL281201A (en) 2021-04-29
AU2019339452A1 (en) 2021-03-25
EP3849598A1 (en) 2021-07-21
KR20210057113A (ko) 2021-05-20
US20210284727A1 (en) 2021-09-16
SG11202102162RA (en) 2021-04-29
WO2020055975A1 (en) 2020-03-19

Similar Documents

Publication Publication Date Title
JP2022500081A (ja) 抗ｔｒｅｍ−２アゴニスト抗体
US12540175B2 (en) Anti-ApoE antibodies
JP6900500B2 (ja) 抗Ｎ３ｐＧｌｕアミロイドベータペプチド抗体およびその使用
CN104602708B (zh) 痴呆症治疗药或预防药
US20150315267A1 (en) A method of reducing brain amyloid plaques using anti-ab antibodies
US20230130218A1 (en) Immunotherapeutic modulation of amyloidogenic disease using non-fibrillogenic, non-amyloidogenic polymerized proteins and peptides
US12116407B2 (en) Methods of treating neurodegenerative diseases
CN116348487A (zh) 抗淀粉样β抗体
Li et al. Prophylactic vaccine based on pyroglutamate-3 amyloid β generates strong antibody response and rescues cognitive decline in Alzheimer’s disease model mice
JP2022528459A (ja) 融合構築物及びその使用
CN120858110A (zh) 用抗Aβ抗体治疗神经病症的方法
US20130034545A1 (en) Treatment of traumatic brain injury using antibodies to lysophosphatidic acid
US20250163136A1 (en) Anti-transthyretin (ttr) binding proteins and uses thereof
JP2026504928A (ja) Ｌｉｌｒｂ４／ｉｌｔ３アンタゴニスト組成物およびその使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220909

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220909

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230829

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231128

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240319